<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166322</url>
  </required_header>
  <id_info>
    <org_study_id>DYN-SPECT-Pogarell</org_study_id>
    <secondary_id>EK076/03</secondary_id>
    <nct_id>NCT00166322</nct_id>
  </id_info>
  <brief_title>Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      This study is an investigation of the dopaminergic neurotransmission in patients with
      schizophrenia, patients at risk for the development of schizophrenia, and healthy controls
      using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging
      technique under amphetamine challenge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dopamine receptor availability</measure>
    <time_frame>cross-sectional</time_frame>
  </primary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IBZM-SPECT (bolus and constant infusion paradigm)</intervention_name>
    <description>single IBZM-SPECT assessment at study inclusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia (currently unmedicated)

          -  Subjects at risk for the development of schizophrenia (prodromal symptoms)

          -  Healthy subjects

          -  Written informed consent

        Exclusion Criteria:

          -  Neurological or severe somatic disorders

          -  Women during pregnancy or lactation

          -  Occupational exposition to radiation &gt; 15mSv

          -  Medication known to interfere with IBZM

          -  Contraindications for the use of amphetamine challenge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Pogarell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Psychiatry, University of Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Tatsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Nuclear Medicine, University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Psychiatry</name>
      <address>
        <city>Munich</city>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Nuclear Medicine</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>O. Pogarell, MD</name_title>
    <organization>University of Munich</organization>
  </responsible_party>
  <keyword>IBZM-SPECT</keyword>
  <keyword>Amphetamine Challenge</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>dopaminergic neurotransmission</keyword>
  <keyword>Persons at risk for the development of schizophrenia</keyword>
  <keyword>healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

